Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
December 23, 2015
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma
December 18, 2015
Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
December 17, 2015
BMS and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program
December 14, 2015
Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
December 11, 2015
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2015 on January 28
December 10, 2015
AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
December 8, 2015
Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.
December 8, 2015
Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton University
December 8, 2015
Bristol-Myers Squibb Announces Dividend Increase
December 5, 2015
New Longer-Term Data for Empliciti (elotuzumab) Showed a Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma
December 4, 2015
Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation’s 2015 Collaborator Award
December 1, 2015
Bristol-Myers Squibb Foundation Marks World AIDS Day with Grants Totaling More than $3.5M for HIV and Cervical and Breast Cancer Programs in Africa
November 30, 2015
Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
November 30, 2015
Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers at the 57th Annual Meeting & Exposition of the American Society of Hematology
November 27, 2015
Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
November 24, 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorization Application
November 24, 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
November 23, 2015
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Therapy1
November 18, 2015
New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma
November 16, 2015
U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma
November 16, 2015
Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD
November 12, 2015
Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress
November 11, 2015
Bristol-Myers Squibb Foundation Awards Five Grants Totaling More than $2.77M to Programs Supporting Post-9/11 Military Veterans, their Families and Caregivers
November 5, 2015
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma
November 5, 2015
Bristol-Myers Squibb to Present Data from 24 Abstracts in Immunoscience at the American College of Rheumatology (ACR) 2015 Congress
November 3, 2015
Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
November 3, 2015
Bristol-Myers Squibb to Present at Credit Suisse 2015 Health Care Conference
November 2, 2015
Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
October 28, 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma
October 28, 2015
Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product
October 27, 2015
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 23, 2015
Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments
October 21, 2015
Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD
October 15, 2015
NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4
October 15, 2015
Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
October 15, 2015
Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 13, 2015
Bristol-Myers Squibb's Ready. Raise. Rise.™ Recognizes 23 Cancer Advocacy Groups in Immuno-Oncology Research Awareness Campaign
October 9, 2015
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients
October 6, 2015
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
October 1, 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
September 28, 2015
Bristol-Myers Squibb Launches Working Together for Patients, a Program Highlighting the Company’s Commitment to Patients
September 28, 2015
REPEAT/Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
September 27, 2015
Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
September 26, 2015
Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
September 25, 2015
Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma
September 25, 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
September 25, 2015
Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program
September 24, 2015
CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
September 24, 2015
Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
September 24, 2015
Bristol-Myers Squibb to Take Part in Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
September 22, 2015
Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
September 18, 2015
Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Living with HIV in Tanzania
September 17, 2015
Bristol-Myers Squibb Announces Dividend
September 16, 2015
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma
September 10, 2015
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
September 10, 2015
Bristol-Myers Squibb Employees Cycle Nearly 2,900 Miles Across the Country to Raise Money for Cancer Research
September 10, 2015
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
September 9, 2015
Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
September 7, 2015
New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
September 7, 2015
Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
September 2, 2015
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
September 2, 2015
Bristol-Myers Squibb to Present New Data from its Immuno-Oncology Clinical Development Programs at 16th World Conference on Lung Cancer
September 2, 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
September 1, 2015
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
August 31, 2015
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases
August 30, 2015
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies
August 13, 2015
FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase
August 12, 2015
U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma
August 4, 2015
Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients
August 3, 2015
Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
July 29, 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
July 27, 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
July 24, 2015
FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3
July 23, 2015
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 23, 2015
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe
July 21, 2015
Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
July 21, 2015
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
July 20, 2015
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer
July 20, 2015
CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
July 16, 2015
European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults
July 15, 2015
MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
June 25, 2015
Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
June 19, 2015
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients
June 18, 2015
Bristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23
June 11, 2015
Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership at the 20th Congress of the European Hematology Association
June 9, 2015
New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis
June 3, 2015
Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting
June 2, 2015
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine
June 2, 2015
Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
June 1, 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
May 31, 2015
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial
May 31, 2015
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma
May 29, 2015
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma
May 29, 2015
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial
May 28, 2015
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 27, 2015
Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
May 22, 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients
May 20, 2015
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
May 13, 2015
Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma
May 12, 2015
Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities
May 12, 2015
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tender Offer
May 4, 2015
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference
April 29, 2015
Bristol-Myers Squibb Prices €1.15 Billion of Senior Notes
April 29, 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma
April 29, 2015
Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference
April 28, 2015
Bristol-Myers Squibb Reports First Quarter Financial Results
April 17, 2015
CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 16, 2015
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
April 6, 2015
Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases
March 27, 2015
Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28
March 24, 2015
Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases
March 12, 2015
Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3
March 4, 2015
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer
March 4, 2015
Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab)
March 2, 2015
Bristol-Myers Squibb Announces Dividend
February 27, 2015
U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
February 26, 2015
ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir
February 26, 2015
Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies
February 24, 2015
Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference
February 5, 2015
Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference
January 29, 2015
U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz(TM) (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults
January 29, 2015
U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults
January 27, 2015
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results
January 20, 2015
Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman
January 13, 2015
Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors
January 11, 2015
CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early
January 5, 2015
Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases